241 related articles for article (PubMed ID: 32615707)
21. Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation.
Marchingo JM; Sinclair LV; Howden AJ; Cantrell DA
Elife; 2020 Feb; 9():. PubMed ID: 32022686
[TBL] [Abstract][Full Text] [Related]
22. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
23. An update on molecular biology of thyroid cancers.
Omur O; Baran Y
Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies and thyroid cancer: an update.
de la Fouchardiere C; Droz JP
Anticancer Drugs; 2011 Aug; 22(7):688-99. PubMed ID: 21200314
[TBL] [Abstract][Full Text] [Related]
25. Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets.
Fagin JA
Endocrinology; 2002 Jun; 143(6):2025-8. PubMed ID: 12021165
[No Abstract] [Full Text] [Related]
26. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
27. Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How.
Bröer S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32859034
[TBL] [Abstract][Full Text] [Related]
28. Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.
Lalami Y; Awada A
Curr Opin Oncol; 2011 May; 23(3):235-40. PubMed ID: 21330922
[TBL] [Abstract][Full Text] [Related]
29. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
30. Target therapies for radioiodine refractory advanced thyroid tumors.
Schlumberger M
J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
[TBL] [Abstract][Full Text] [Related]
31. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells.
Jensen K; Bikas A; Patel A; Kushchayeva Y; Costello J; McDaniel D; Burman K; Vasko V
Endocr Relat Cancer; 2017 Mar; 24(3):147-156. PubMed ID: 28137980
[TBL] [Abstract][Full Text] [Related]
32. Targeting autophagy in thyroid cancers.
Wei W; Hardin H; Luo QY
Endocr Relat Cancer; 2019 Apr; 26(4):R181-R194. PubMed ID: 30667364
[TBL] [Abstract][Full Text] [Related]
33. Medullary thyroid cancer: molecular biology and novel molecular therapies.
Cakir M; Grossman AB
Neuroendocrinology; 2009; 90(4):323-48. PubMed ID: 19468197
[TBL] [Abstract][Full Text] [Related]
34. New Insights in Thyroid Cancer and p53 Family Proteins.
Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
[TBL] [Abstract][Full Text] [Related]
35. KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC.
Wei X; Cai S; Boohaker RJ; Fried J; Li Y; Hu L; Pan Y; Cheng R; Zhang S; Tian Y; Gao M; Xu B
Endocr Relat Cancer; 2019 Jan; 26(1):141-151. PubMed ID: 30400007
[TBL] [Abstract][Full Text] [Related]
36. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells.
Kim CS; Cho SH; Chun HS; Lee SY; Endou H; Kanai Y; Kim DK
Biol Pharm Bull; 2008 Jun; 31(6):1096-100. PubMed ID: 18520037
[TBL] [Abstract][Full Text] [Related]
37. Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism.
Badziong J; Ting S; Synoracki S; Tiedje V; Brix K; Brabant G; Moeller LC; Schmid KW; Fuhrer D; Zwanziger D
Eur J Endocrinol; 2017 Sep; 177(3):243-250. PubMed ID: 28576880
[TBL] [Abstract][Full Text] [Related]
38. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
Fröhlich E; Wahl R
Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
[TBL] [Abstract][Full Text] [Related]
39.
Krishnamoorthy GP; Davidson NR; Leach SD; Zhao Z; Lowe SW; Lee G; Landa I; Nagarajah J; Saqcena M; Singh K; Wendel HG; Dogan S; Tamarapu PP; Blenis J; Ghossein RA; Knauf JA; Rätsch G; Fagin JA
Cancer Discov; 2019 Feb; 9(2):264-281. PubMed ID: 30305285
[TBL] [Abstract][Full Text] [Related]
40. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.
Wongthai P; Hagiwara K; Miyoshi Y; Wiriyasermkul P; Wei L; Ohgaki R; Kato I; Hamase K; Nagamori S; Kanai Y
Cancer Sci; 2015 Mar; 106(3):279-86. PubMed ID: 25580517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
